Welcome to our dedicated page for Lensar SEC filings (Ticker: LNSR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The LENSAR, Inc. (LNSR) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a Nasdaq-listed medical device and global medical technology company. LENSAR files reports with the U.S. Securities and Exchange Commission that cover its financial performance, corporate governance, and significant corporate events.
Current reports on Form 8-K include items such as quarterly results announcements, scheduling of stockholder meetings, and the outcome of the special meeting at which stockholders approved the merger agreement with Alcon Research, LLC. For example, an 8-K dated July 2, 2025, details the vote to adopt the merger agreement under which Alcon intends to acquire LENSAR, with LENSAR surviving as a wholly owned subsidiary of Alcon Research, LLC upon completion of the transaction.
LENSAR also files a definitive proxy statement on Schedule 14A, which describes the annual meeting of stockholders, director elections, ratification of the independent registered public accounting firm, and aspects of corporate governance and executive and director compensation. The proxy materials outline board structure, committee responsibilities, risk oversight, and equity compensation plans.
Through Stock Titan, users can access these filings as they are made available on EDGAR and review key sections with AI-powered assistance. Summaries can help explain complex topics such as merger proposals, non-GAAP financial measures referenced in earnings-related filings, and stockholder voting procedures. This page is a resource for understanding how LENSAR reports its operations, governance, and the progress of its planned acquisition by Alcon.
LENSAR (NASDAQ:LNSR) filed additional proxy materials for its pending $14 per-share cash merger with Alcon. The supplement answers shareholder demand letters claiming the May 19 definitive proxy omitted material facts, potentially violating Sections 14(a)/20(a). To pre-empt litigation, LENSAR adds disclosures while denying wrongdoing.
Key additions:
- Confirms no discussions of post-merger employment or equity for executives during Feb 21-26 2025 talks.
- Updates Wells Fargo Securities comps: mean EV/2025E revenue 3.9×, median 2.8×; LENSAR traded at 5.2×.
- WFS selects 4.00-5.25× 2025E and 3.00-4.00× 2026E revenue multiples, implying $12.27–$16.51 per share versus $14.00 cash offer and $16.03 discounted amount.
- Expanded precedent-transaction table (4.0×–6.5× LTM revenue).
The board’s recommendation and the July 2 2025 special-meeting timetable are unchanged.